JP2008525442A - 鉄を含む組成物 - Google Patents
鉄を含む組成物 Download PDFInfo
- Publication number
- JP2008525442A JP2008525442A JP2007548207A JP2007548207A JP2008525442A JP 2008525442 A JP2008525442 A JP 2008525442A JP 2007548207 A JP2007548207 A JP 2007548207A JP 2007548207 A JP2007548207 A JP 2007548207A JP 2008525442 A JP2008525442 A JP 2008525442A
- Authority
- JP
- Japan
- Prior art keywords
- iron
- ferric
- complex
- forms
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 title claims abstract description 624
- 229910052742 iron Inorganic materials 0.000 title claims abstract description 308
- 239000000203 mixture Substances 0.000 title claims abstract description 199
- 238000010521 absorption reaction Methods 0.000 claims abstract description 56
- 150000007524 organic acids Chemical class 0.000 claims abstract description 33
- 206010022971 Iron Deficiencies Diseases 0.000 claims abstract description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 31
- 238000011282 treatment Methods 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 28
- 239000003623 enhancer Substances 0.000 claims abstract description 10
- 229960003284 iron Drugs 0.000 claims description 304
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 114
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 75
- 235000010323 ascorbic acid Nutrition 0.000 claims description 47
- 239000011668 ascorbic acid Substances 0.000 claims description 47
- 229960005070 ascorbic acid Drugs 0.000 claims description 40
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 40
- 241001465754 Metazoa Species 0.000 claims description 31
- 239000001384 succinic acid Substances 0.000 claims description 31
- -1 iron amino acid Chemical class 0.000 claims description 28
- 241000282412 Homo Species 0.000 claims description 25
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims description 24
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 22
- 229960000304 folic acid Drugs 0.000 claims description 22
- 235000019152 folic acid Nutrition 0.000 claims description 22
- 239000011724 folic acid Substances 0.000 claims description 22
- 210000004369 blood Anatomy 0.000 claims description 21
- 239000008280 blood Substances 0.000 claims description 21
- 238000003860 storage Methods 0.000 claims description 19
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 claims description 15
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 15
- 150000002506 iron compounds Chemical class 0.000 claims description 15
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 14
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 claims description 14
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims description 13
- 235000002332 ferrous fumarate Nutrition 0.000 claims description 13
- 239000011773 ferrous fumarate Substances 0.000 claims description 13
- 229960000225 ferrous fumarate Drugs 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 238000013270 controlled release Methods 0.000 claims description 12
- 229960001781 ferrous sulfate Drugs 0.000 claims description 12
- 235000003891 ferrous sulphate Nutrition 0.000 claims description 12
- 239000011790 ferrous sulphate Substances 0.000 claims description 12
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 12
- 235000001014 amino acid Nutrition 0.000 claims description 11
- 229940024606 amino acid Drugs 0.000 claims description 11
- 150000004698 iron complex Chemical class 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 10
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 9
- 239000004277 Ferrous carbonate Substances 0.000 claims description 9
- 150000000996 L-ascorbic acids Chemical class 0.000 claims description 9
- 229930003268 Vitamin C Natural products 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- RAQDACVRFCEPDA-UHFFFAOYSA-L ferrous carbonate Chemical compound [Fe+2].[O-]C([O-])=O RAQDACVRFCEPDA-UHFFFAOYSA-L 0.000 claims description 9
- 235000019268 ferrous carbonate Nutrition 0.000 claims description 9
- 229960004652 ferrous carbonate Drugs 0.000 claims description 9
- 229910000015 iron(II) carbonate Inorganic materials 0.000 claims description 9
- 235000019154 vitamin C Nutrition 0.000 claims description 9
- 239000011718 vitamin C Substances 0.000 claims description 9
- 229940124532 absorption promoter Drugs 0.000 claims description 8
- 229940072107 ascorbate Drugs 0.000 claims description 8
- 150000002505 iron Chemical class 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 230000000087 stabilizing effect Effects 0.000 claims description 7
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 claims description 6
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 6
- VCJMYUPGQJHHFU-UHFFFAOYSA-N iron(3+);trinitrate Chemical compound [Fe+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O VCJMYUPGQJHHFU-UHFFFAOYSA-N 0.000 claims description 6
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 claims description 6
- NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical compound [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 241000282414 Homo sapiens Species 0.000 claims description 5
- 150000001720 carbohydrates Chemical class 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 235000013924 ferrous gluconate Nutrition 0.000 claims description 5
- 239000004222 ferrous gluconate Substances 0.000 claims description 5
- 229960001645 ferrous gluconate Drugs 0.000 claims description 5
- IEECXTSVVFWGSE-UHFFFAOYSA-M iron(3+);oxygen(2-);hydroxide Chemical compound [OH-].[O-2].[Fe+3] IEECXTSVVFWGSE-UHFFFAOYSA-M 0.000 claims description 5
- 229910021506 iron(II) hydroxide Inorganic materials 0.000 claims description 5
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 claims description 5
- 239000004310 lactic acid Substances 0.000 claims description 5
- 235000014655 lactic acid Nutrition 0.000 claims description 5
- 229940127234 oral contraceptive Drugs 0.000 claims description 5
- 239000003539 oral contraceptive agent Substances 0.000 claims description 5
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 4
- CZNVSLGYWMSMKE-OPDGVEILSA-K Ferric gluconate Chemical compound [Fe+3].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O CZNVSLGYWMSMKE-OPDGVEILSA-K 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 4
- 235000011054 acetic acid Nutrition 0.000 claims description 4
- MDXRFOWKIZPNTA-UHFFFAOYSA-L butanedioate;iron(2+) Chemical compound [Fe+2].[O-]C(=O)CCC([O-])=O MDXRFOWKIZPNTA-UHFFFAOYSA-L 0.000 claims description 4
- 208000020832 chronic kidney disease Diseases 0.000 claims description 4
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 4
- 235000015165 citric acid Nutrition 0.000 claims description 4
- 235000019850 ferrous citrate Nutrition 0.000 claims description 4
- 239000011640 ferrous citrate Substances 0.000 claims description 4
- 229960001604 ferrous succinate Drugs 0.000 claims description 4
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 4
- 229910000360 iron(III) sulfate Inorganic materials 0.000 claims description 4
- 239000001630 malic acid Substances 0.000 claims description 4
- 235000011090 malic acid Nutrition 0.000 claims description 4
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 claims description 4
- 229940078042 polysaccharide iron complex Drugs 0.000 claims description 4
- 230000000153 supplemental effect Effects 0.000 claims description 4
- SFOKDWPZOYRZFF-UHFFFAOYSA-H 2,3-dihydroxybutanedioate;iron(3+) Chemical compound [Fe+3].[Fe+3].[O-]C(=O)C(O)C(O)C([O-])=O.[O-]C(=O)C(O)C(O)C([O-])=O.[O-]C(=O)C(O)C(O)C([O-])=O SFOKDWPZOYRZFF-UHFFFAOYSA-H 0.000 claims description 3
- QXKAIJAYHKCRRA-UHFFFAOYSA-N D-lyxonic acid Natural products OCC(O)C(O)C(O)C(O)=O QXKAIJAYHKCRRA-UHFFFAOYSA-N 0.000 claims description 3
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 claims description 3
- SBJKKFFYIZUCET-UHFFFAOYSA-N Dehydroascorbic acid Natural products OCC(O)C1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-UHFFFAOYSA-N 0.000 claims description 3
- 239000005955 Ferric phosphate Substances 0.000 claims description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- 229910021578 Iron(III) chloride Inorganic materials 0.000 claims description 3
- JPIJQSOTBSSVTP-STHAYSLISA-N L-threonic acid Chemical compound OC[C@H](O)[C@@H](O)C(O)=O JPIJQSOTBSSVTP-STHAYSLISA-N 0.000 claims description 3
- QXKAIJAYHKCRRA-NUNKFHFFSA-N L-xylonic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)C(O)=O QXKAIJAYHKCRRA-NUNKFHFFSA-N 0.000 claims description 3
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 3
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- 239000004260 Potassium ascorbate Substances 0.000 claims description 3
- 229940009098 aspartate Drugs 0.000 claims description 3
- 235000010376 calcium ascorbate Nutrition 0.000 claims description 3
- 229940047036 calcium ascorbate Drugs 0.000 claims description 3
- 239000011692 calcium ascorbate Substances 0.000 claims description 3
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 claims description 3
- 229960001231 choline Drugs 0.000 claims description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 3
- 150000001860 citric acid derivatives Chemical class 0.000 claims description 3
- 235000020960 dehydroascorbic acid Nutrition 0.000 claims description 3
- 239000011615 dehydroascorbic acid Substances 0.000 claims description 3
- 235000007144 ferric diphosphate Nutrition 0.000 claims description 3
- 239000011706 ferric diphosphate Substances 0.000 claims description 3
- 229960004887 ferric hydroxide Drugs 0.000 claims description 3
- 229940032958 ferric phosphate Drugs 0.000 claims description 3
- 229940036404 ferric pyrophosphate Drugs 0.000 claims description 3
- CADNYOZXMIKYPR-UHFFFAOYSA-B ferric pyrophosphate Chemical compound [Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O CADNYOZXMIKYPR-UHFFFAOYSA-B 0.000 claims description 3
- IMBKASBLAKCLEM-UHFFFAOYSA-L ferrous ammonium sulfate (anhydrous) Chemical compound [NH4+].[NH4+].[Fe+2].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O IMBKASBLAKCLEM-UHFFFAOYSA-L 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- 150000002306 glutamic acid derivatives Chemical class 0.000 claims description 3
- WBJZTOZJJYAKHQ-UHFFFAOYSA-K iron(3+) phosphate Chemical compound [Fe+3].[O-]P([O-])([O-])=O WBJZTOZJJYAKHQ-UHFFFAOYSA-K 0.000 claims description 3
- RUTXIHLAWFEWGM-UHFFFAOYSA-H iron(3+) sulfate Chemical compound [Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O RUTXIHLAWFEWGM-UHFFFAOYSA-H 0.000 claims description 3
- 229910000462 iron(III) oxide hydroxide Inorganic materials 0.000 claims description 3
- 229910000399 iron(III) phosphate Inorganic materials 0.000 claims description 3
- 229940056902 l- threonic acid Drugs 0.000 claims description 3
- 229940074358 magnesium ascorbate Drugs 0.000 claims description 3
- AIOKQVJVNPDJKA-ZZMNMWMASA-L magnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-olate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] AIOKQVJVNPDJKA-ZZMNMWMASA-L 0.000 claims description 3
- 150000004701 malic acid derivatives Chemical class 0.000 claims description 3
- 229910052748 manganese Inorganic materials 0.000 claims description 3
- 239000011572 manganese Substances 0.000 claims description 3
- 229960003330 pentetic acid Drugs 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 235000019275 potassium ascorbate Nutrition 0.000 claims description 3
- 229940017794 potassium ascorbate Drugs 0.000 claims description 3
- CONVKSGEGAVTMB-RXSVEWSESA-M potassium-L-ascorbate Chemical compound [K+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] CONVKSGEGAVTMB-RXSVEWSESA-M 0.000 claims description 3
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims description 3
- 235000010378 sodium ascorbate Nutrition 0.000 claims description 3
- 229960005055 sodium ascorbate Drugs 0.000 claims description 3
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 claims description 3
- 150000003443 succinic acid derivatives Chemical class 0.000 claims description 3
- 238000013268 sustained release Methods 0.000 claims description 3
- 239000012730 sustained-release form Substances 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- 235000019156 vitamin B Nutrition 0.000 claims description 3
- 239000011720 vitamin B Substances 0.000 claims description 3
- OHZCFWMJMWFNFP-ZVGUSBNCSA-L (2r,3r)-2,3-dihydroxybutanedioate;iron(2+) Chemical compound [Fe+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O OHZCFWMJMWFNFP-ZVGUSBNCSA-L 0.000 claims description 2
- WNDUPUMWHYAJOR-SADXPQEKSA-K (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;2-hydroxypropane-1,2,3-tricarboxylate;iron(3+) Chemical compound [Fe+3].OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WNDUPUMWHYAJOR-SADXPQEKSA-K 0.000 claims description 2
- XXDVUVPHJGZWQC-QHTZZOMLSA-L (2s)-2-amino-5-hydroxy-5-oxopentanoate;iron(2+) Chemical compound [Fe+2].[O-]C(=O)[C@@H](N)CCC(O)=O.[O-]C(=O)[C@@H](N)CCC(O)=O XXDVUVPHJGZWQC-QHTZZOMLSA-L 0.000 claims description 2
- YSFIPRFOHJQXJF-VMJVVOMYSA-N (r)-[(2s,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C([C@H]([C@H](C1)C=C)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21.C([C@H]([C@H](C1)C=C)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 YSFIPRFOHJQXJF-VMJVVOMYSA-N 0.000 claims description 2
- MDAXKAUIABOHTD-UHFFFAOYSA-N 1,4,8,11-tetraazacyclotetradecane Chemical compound C1CNCCNCCCNCCNC1 MDAXKAUIABOHTD-UHFFFAOYSA-N 0.000 claims description 2
- CBEYZWBXIPZYNH-UHFFFAOYSA-J 1,5-dihydroxypentan-3-yl phosphate;2,3-dihydroxypropyl phosphate;iron(2+) Chemical compound [Fe+2].[Fe+2].OCC(O)COP([O-])([O-])=O.OCCC(CCO)OP([O-])([O-])=O CBEYZWBXIPZYNH-UHFFFAOYSA-J 0.000 claims description 2
- KMHSUNDEGHRBNV-UHFFFAOYSA-N 2,4-dichloropyrimidine-5-carbonitrile Chemical compound ClC1=NC=C(C#N)C(Cl)=N1 KMHSUNDEGHRBNV-UHFFFAOYSA-N 0.000 claims description 2
- NLGYGIHWYOPKIX-UHFFFAOYSA-N 2-[carboxymethyl(methyl)amino]acetic acid;iron Chemical compound [Fe].OC(=O)CN(C)CC(O)=O NLGYGIHWYOPKIX-UHFFFAOYSA-N 0.000 claims description 2
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 claims description 2
- OTTPVANZKZRSBY-UHFFFAOYSA-N 2-aminoacetic acid;iron Chemical compound [Fe].NCC(O)=O.NCC(O)=O OTTPVANZKZRSBY-UHFFFAOYSA-N 0.000 claims description 2
- ZEYKLMDPUOVUCR-UHFFFAOYSA-N 2-chloro-5-(trifluoromethyl)benzenesulfonyl chloride Chemical compound FC(F)(F)C1=CC=C(Cl)C(S(Cl)(=O)=O)=C1 ZEYKLMDPUOVUCR-UHFFFAOYSA-N 0.000 claims description 2
- KRUJOKMDEHYPOP-UHFFFAOYSA-L 2-hydroxybutanedioate;iron(2+) Chemical compound [Fe+2].[O-]C(=O)C(O)CC([O-])=O KRUJOKMDEHYPOP-UHFFFAOYSA-L 0.000 claims description 2
- OAVRWNUUOUXDFH-UHFFFAOYSA-H 2-hydroxypropane-1,2,3-tricarboxylate;manganese(2+) Chemical compound [Mn+2].[Mn+2].[Mn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O OAVRWNUUOUXDFH-UHFFFAOYSA-H 0.000 claims description 2
- LIPRKYKMVQPYPG-UHFFFAOYSA-N 3-Hydroxy-2H-pyran-2-one Chemical compound OC1=CC=COC1=O LIPRKYKMVQPYPG-UHFFFAOYSA-N 0.000 claims description 2
- CIXCLWDVLIFJBV-UHFFFAOYSA-N 3-hydroxy-1H-pyridin-2-one iron(3+) Chemical compound [Fe+3].OC1=CC=CNC1=O CIXCLWDVLIFJBV-UHFFFAOYSA-N 0.000 claims description 2
- 108010088751 Albumins Proteins 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- DKKCQDROTDCQOR-UHFFFAOYSA-L Ferrous lactate Chemical compound [Fe+2].CC(O)C([O-])=O.CC(O)C([O-])=O DKKCQDROTDCQOR-UHFFFAOYSA-L 0.000 claims description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- QXKAIJAYHKCRRA-PZGQECOJSA-N L-lyxonic acid Chemical class OC[C@H](O)[C@@H](O)[C@@H](O)C(O)=O QXKAIJAYHKCRRA-PZGQECOJSA-N 0.000 claims description 2
- 108010063045 Lactoferrin Proteins 0.000 claims description 2
- 102100032241 Lactotransferrin Human genes 0.000 claims description 2
- 229910002651 NO3 Inorganic materials 0.000 claims description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
- WBFHLAUVRLNSEF-UHFFFAOYSA-N SC([Fe])=S Chemical compound SC([Fe])=S WBFHLAUVRLNSEF-UHFFFAOYSA-N 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 229930003270 Vitamin B Natural products 0.000 claims description 2
- JQRLYSGCPHSLJI-UHFFFAOYSA-N [Fe].N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 Chemical compound [Fe].N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 JQRLYSGCPHSLJI-UHFFFAOYSA-N 0.000 claims description 2
- MCDLETWIOVSGJT-UHFFFAOYSA-N acetic acid;iron Chemical compound [Fe].CC(O)=O.CC(O)=O MCDLETWIOVSGJT-UHFFFAOYSA-N 0.000 claims description 2
- 229940009456 adriamycin Drugs 0.000 claims description 2
- FRHBOQMZUOWXQL-UHFFFAOYSA-L ammonium ferric citrate Chemical compound [NH4+].[Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FRHBOQMZUOWXQL-UHFFFAOYSA-L 0.000 claims description 2
- 230000003474 anti-emetic effect Effects 0.000 claims description 2
- 239000002111 antiemetic agent Substances 0.000 claims description 2
- CHYQSXLXQCXPAA-UHFFFAOYSA-H butanedioate;iron(3+) Chemical compound [Fe+3].[Fe+3].[O-]C(=O)CCC([O-])=O.[O-]C(=O)CCC([O-])=O.[O-]C(=O)CCC([O-])=O CHYQSXLXQCXPAA-UHFFFAOYSA-H 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 235000014633 carbohydrates Nutrition 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 229960003266 deferiprone Drugs 0.000 claims description 2
- FWZTTZUKDVJDCM-CEJAUHOTSA-M disodium;(2r,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;iron(3+);oxygen(2-);hydroxide;trihydrate Chemical compound O.O.O.[OH-].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FWZTTZUKDVJDCM-CEJAUHOTSA-M 0.000 claims description 2
- 239000012990 dithiocarbamate Substances 0.000 claims description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N doxorubicine Natural products O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 2
- 229960004642 ferric ammonium citrate Drugs 0.000 claims description 2
- 229960002413 ferric citrate Drugs 0.000 claims description 2
- VEPSWGHMGZQCIN-UHFFFAOYSA-H ferric oxalate Chemical compound [Fe+3].[Fe+3].[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O VEPSWGHMGZQCIN-UHFFFAOYSA-H 0.000 claims description 2
- SRMBQCVUAVULDJ-UHFFFAOYSA-N ferrioxamine b Chemical compound [Fe+3].CC(=O)N([O-])CCCCCNC(=O)CCC(=O)N([O-])CCCCCNC(=O)CCC(=O)N([O-])CCCCCN SRMBQCVUAVULDJ-UHFFFAOYSA-N 0.000 claims description 2
- 229940042644 ferrlecit Drugs 0.000 claims description 2
- 229960002089 ferrous chloride Drugs 0.000 claims description 2
- 229940076136 ferrous iodide Drugs 0.000 claims description 2
- 235000013925 ferrous lactate Nutrition 0.000 claims description 2
- 239000004225 ferrous lactate Substances 0.000 claims description 2
- 229940037907 ferrous lactate Drugs 0.000 claims description 2
- 229940062993 ferrous oxalate Drugs 0.000 claims description 2
- 229940116007 ferrous phosphate Drugs 0.000 claims description 2
- 229940057006 ferrous tartrate Drugs 0.000 claims description 2
- 150000003278 haem Chemical class 0.000 claims description 2
- 239000004313 iron ammonium citrate Substances 0.000 claims description 2
- 235000000011 iron ammonium citrate Nutrition 0.000 claims description 2
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 claims description 2
- DXTCFKRAUYBHRC-UHFFFAOYSA-L iron(2+);dithiocyanate Chemical compound [Fe+2].[S-]C#N.[S-]C#N DXTCFKRAUYBHRC-UHFFFAOYSA-L 0.000 claims description 2
- OWZIYWAUNZMLRT-UHFFFAOYSA-L iron(2+);oxalate Chemical compound [Fe+2].[O-]C(=O)C([O-])=O OWZIYWAUNZMLRT-UHFFFAOYSA-L 0.000 claims description 2
- PVFSDGKDKFSOTB-UHFFFAOYSA-K iron(3+);triacetate Chemical compound [Fe+3].CC([O-])=O.CC([O-])=O.CC([O-])=O PVFSDGKDKFSOTB-UHFFFAOYSA-K 0.000 claims description 2
- YPJCVYYCWSFGRM-UHFFFAOYSA-H iron(3+);tricarbonate Chemical compound [Fe+3].[Fe+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O YPJCVYYCWSFGRM-UHFFFAOYSA-H 0.000 claims description 2
- WHRBSMVATPCWLU-UHFFFAOYSA-K iron(3+);triformate Chemical compound [Fe+3].[O-]C=O.[O-]C=O.[O-]C=O WHRBSMVATPCWLU-UHFFFAOYSA-K 0.000 claims description 2
- LIRDHUDRLFDYAI-UHFFFAOYSA-H iron(3+);trisulfite Chemical compound [Fe+3].[Fe+3].[O-]S([O-])=O.[O-]S([O-])=O.[O-]S([O-])=O LIRDHUDRLFDYAI-UHFFFAOYSA-H 0.000 claims description 2
- 229910000155 iron(II) phosphate Inorganic materials 0.000 claims description 2
- 229910021519 iron(III) oxide-hydroxide Inorganic materials 0.000 claims description 2
- BQZGVMWPHXIKEQ-UHFFFAOYSA-L iron(ii) iodide Chemical compound [Fe+2].[I-].[I-] BQZGVMWPHXIKEQ-UHFFFAOYSA-L 0.000 claims description 2
- SDEKDNPYZOERBP-UHFFFAOYSA-H iron(ii) phosphate Chemical compound [Fe+2].[Fe+2].[Fe+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O SDEKDNPYZOERBP-UHFFFAOYSA-H 0.000 claims description 2
- SHXXPRJOPFJRHA-UHFFFAOYSA-K iron(iii) fluoride Chemical compound F[Fe](F)F SHXXPRJOPFJRHA-UHFFFAOYSA-K 0.000 claims description 2
- 229940029416 iron-dextran complex Drugs 0.000 claims description 2
- CQDYTLPONORKST-UHFFFAOYSA-N iron;4-methylaniline Chemical compound [Fe].CC1=CC=C(N)C=C1 CQDYTLPONORKST-UHFFFAOYSA-N 0.000 claims description 2
- DLAPQHBZCAAVPQ-UHFFFAOYSA-N iron;pentane-2,4-dione Chemical compound [Fe].CC(=O)CC(C)=O DLAPQHBZCAAVPQ-UHFFFAOYSA-N 0.000 claims description 2
- ODBLHEXUDAPZAU-UHFFFAOYSA-N isocitric acid Chemical compound OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 claims description 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 2
- 229940078795 lactoferrin Drugs 0.000 claims description 2
- 235000021242 lactoferrin Nutrition 0.000 claims description 2
- 239000008141 laxative Substances 0.000 claims description 2
- 229940049920 malate Drugs 0.000 claims description 2
- 235000014872 manganese citrate Nutrition 0.000 claims description 2
- 239000011564 manganese citrate Substances 0.000 claims description 2
- 229940097206 manganese citrate Drugs 0.000 claims description 2
- BIBAGCHWEBMFKX-UHFFFAOYSA-N methylidyneiron Chemical compound [Fe]#C BIBAGCHWEBMFKX-UHFFFAOYSA-N 0.000 claims description 2
- 239000004417 polycarbonate Substances 0.000 claims description 2
- 229920000515 polycarbonate Polymers 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 229940083542 sodium Drugs 0.000 claims description 2
- 235000015393 sodium molybdate Nutrition 0.000 claims description 2
- 239000011684 sodium molybdate Substances 0.000 claims description 2
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 claims description 2
- MQBDAEHWGRMADS-XNHLMZCASA-M sodium;(2r,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;iron(3+);oxygen(2-);(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate Chemical compound [O-2].[O-2].[O-2].[Na+].[Fe+3].[Fe+3].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 MQBDAEHWGRMADS-XNHLMZCASA-M 0.000 claims description 2
- XJDIIQYURGDWCL-UHFFFAOYSA-K sodium;iron(3+);2-oxidopropane-1,2,3-tricarboxylate Chemical compound [Na+].[Fe+3].[O-]C(=O)CC([O-])(C([O-])=O)CC([O-])=O XJDIIQYURGDWCL-UHFFFAOYSA-K 0.000 claims description 2
- XWQGIDJIEPIQBD-UHFFFAOYSA-J sodium;iron(3+);phosphonato phosphate Chemical compound [Na+].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O XWQGIDJIEPIQBD-UHFFFAOYSA-J 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 3
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims 2
- 235000011180 diphosphates Nutrition 0.000 claims 2
- 230000010437 erythropoiesis Effects 0.000 claims 2
- 229940056904 zinc ascorbate Drugs 0.000 claims 2
- WWRJFSIRMWUMAE-ZZMNMWMASA-L zinc;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3-hydroxy-5-oxo-2h-furan-4-olate Chemical compound [Zn+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] WWRJFSIRMWUMAE-ZZMNMWMASA-L 0.000 claims 2
- LMSDCGXQALIMLM-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;iron Chemical compound [Fe].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O LMSDCGXQALIMLM-UHFFFAOYSA-N 0.000 claims 1
- BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 102100027211 Albumin Human genes 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical group O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 1
- ODGRMQBYMRPROY-RHLRHBBGSA-L [Fe+2].C(N)([S-])=S.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C(N)([S-])=S Chemical compound [Fe+2].C(N)([S-])=S.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C(N)([S-])=S ODGRMQBYMRPROY-RHLRHBBGSA-L 0.000 claims 1
- XGGLLRJQCZROSE-UHFFFAOYSA-K ammonium iron(iii) sulfate Chemical compound [NH4+].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O XGGLLRJQCZROSE-UHFFFAOYSA-K 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- SXAWSYZURCZSDX-UHFFFAOYSA-B hydron;[hydroxy(oxido)phosphoryl] hydrogen phosphate;2-hydroxypropane-1,2,3-tricarboxylate;iron(3+);phosphonato phosphate Chemical compound [H+].[H+].[H+].[H+].[H+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].OP([O-])(=O)OP(O)([O-])=O.OP([O-])(=O)OP(O)([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O SXAWSYZURCZSDX-UHFFFAOYSA-B 0.000 claims 1
- BZWGENDDUSTHIR-UHFFFAOYSA-N iron phosphorous acid Chemical compound [Fe].P(O)(O)O BZWGENDDUSTHIR-UHFFFAOYSA-N 0.000 claims 1
- 230000002475 laxative effect Effects 0.000 claims 1
- 235000006748 manganese carbonate Nutrition 0.000 claims 1
- 239000011656 manganese carbonate Substances 0.000 claims 1
- 229940093474 manganese carbonate Drugs 0.000 claims 1
- 229940099596 manganese sulfate Drugs 0.000 claims 1
- 235000007079 manganese sulphate Nutrition 0.000 claims 1
- 239000011702 manganese sulphate Substances 0.000 claims 1
- 229910000016 manganese(II) carbonate Inorganic materials 0.000 claims 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims 1
- XMWCXZJXESXBBY-UHFFFAOYSA-L manganese(ii) carbonate Chemical compound [Mn+2].[O-]C([O-])=O XMWCXZJXESXBBY-UHFFFAOYSA-L 0.000 claims 1
- 235000006408 oxalic acid Nutrition 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 229940048084 pyrophosphate Drugs 0.000 claims 1
- MKWYFZFMAMBPQK-UHFFFAOYSA-J sodium feredetate Chemical compound [Na+].[Fe+3].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O MKWYFZFMAMBPQK-UHFFFAOYSA-J 0.000 claims 1
- ZNCPFRVNHGOPAG-UHFFFAOYSA-L sodium oxalate Chemical compound [Na+].[Na+].[O-]C(=O)C([O-])=O ZNCPFRVNHGOPAG-UHFFFAOYSA-L 0.000 claims 1
- 229940039790 sodium oxalate Drugs 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 abstract description 52
- 235000005911 diet Nutrition 0.000 abstract description 21
- 235000016709 nutrition Nutrition 0.000 abstract description 16
- 208000035475 disorder Diseases 0.000 abstract description 14
- 235000005985 organic acids Nutrition 0.000 abstract description 14
- 230000037213 diet Effects 0.000 abstract description 6
- 230000002265 prevention Effects 0.000 abstract description 4
- 230000006641 stabilisation Effects 0.000 abstract description 4
- 238000011105 stabilization Methods 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 3
- 230000006872 improvement Effects 0.000 abstract description 3
- 239000013589 supplement Substances 0.000 description 52
- 230000009469 supplementation Effects 0.000 description 28
- GIPOFCXYHMWROH-UHFFFAOYSA-L 2-aminoacetate;iron(2+) Chemical compound [Fe+2].NCC([O-])=O.NCC([O-])=O GIPOFCXYHMWROH-UHFFFAOYSA-L 0.000 description 18
- 239000002552 dosage form Substances 0.000 description 16
- 230000000968 intestinal effect Effects 0.000 description 16
- 230000000378 dietary effect Effects 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 13
- 229940093915 gynecological organic acid Drugs 0.000 description 13
- 159000000014 iron salts Chemical class 0.000 description 13
- 210000003743 erythrocyte Anatomy 0.000 description 11
- 238000009472 formulation Methods 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 230000008929 regeneration Effects 0.000 description 8
- 238000011069 regeneration method Methods 0.000 description 8
- 230000002496 gastric effect Effects 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 102000001554 Hemoglobins Human genes 0.000 description 6
- 108010054147 Hemoglobins Proteins 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 210000001842 enterocyte Anatomy 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 210000000813 small intestine Anatomy 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 235000008206 alpha-amino acids Nutrition 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 208000007882 Gastritis Diseases 0.000 description 3
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229960001484 edetic acid Drugs 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000001502 supplementing effect Effects 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 206010017943 Gastrointestinal conditions Diseases 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000007894 caplet Substances 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 150000002224 folic acids Chemical class 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 229910052751 metal Chemical group 0.000 description 2
- 239000002184 metal Chemical group 0.000 description 2
- IBVJFULICYLKCE-BDVNFPICSA-N methyl-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]carbamodithioic acid Chemical compound SC(=S)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO IBVJFULICYLKCE-BDVNFPICSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 235000002949 phytic acid Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000007065 protein hydrolysis Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- CNHDIAIOKMXOLK-UHFFFAOYSA-N toluquinol Chemical compound CC1=CC(O)=CC=C1O CNHDIAIOKMXOLK-UHFFFAOYSA-N 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
- ZITFTYGHYGPDAV-UHFFFAOYSA-L 2-aminoacetic acid;iron(2+);sulfate Chemical compound [H+].[Fe+2].NCC([O-])=O.[O-]S([O-])(=O)=O ZITFTYGHYGPDAV-UHFFFAOYSA-L 0.000 description 1
- RPERJPYDELTDMR-UHFFFAOYSA-K 2-hydroxyethyl(trimethyl)azanium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound C[N+](C)(C)CCO.C[N+](C)(C)CCO.C[N+](C)(C)CCO.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O RPERJPYDELTDMR-UHFFFAOYSA-K 0.000 description 1
- FPFSGDXIBUDDKZ-UHFFFAOYSA-N 3-decyl-2-hydroxycyclopent-2-en-1-one Chemical compound CCCCCCCCCCC1=C(O)C(=O)CC1 FPFSGDXIBUDDKZ-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010065973 Iron Overload Diseases 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940010514 ammonium ferrous sulfate Drugs 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 229940086704 ascorbic acid 200 mg Drugs 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 229960003257 choline citrate Drugs 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000013110 gastrectomy Methods 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 208000010501 heavy metal poisoning Diseases 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 244000000053 intestinal parasite Species 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 150000002500 ions Chemical group 0.000 description 1
- 229940087654 iron carbonyl Drugs 0.000 description 1
- ATEAWHILRRXHPW-UHFFFAOYSA-J iron(2+);phosphonato phosphate Chemical compound [Fe+2].[Fe+2].[O-]P([O-])(=O)OP([O-])([O-])=O ATEAWHILRRXHPW-UHFFFAOYSA-J 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 229960004400 levonorgestrel Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- LBSANEJBGMCTBH-UHFFFAOYSA-N manganate Chemical compound [O-][Mn]([O-])(=O)=O LBSANEJBGMCTBH-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 208000014081 polyp of colon Diseases 0.000 description 1
- KYKNRZGSIGMXFH-ZVGUSBNCSA-M potassium bitartrate Chemical compound [K+].OC(=O)[C@H](O)[C@@H](O)C([O-])=O KYKNRZGSIGMXFH-ZVGUSBNCSA-M 0.000 description 1
- 239000001472 potassium tartrate Substances 0.000 description 1
- 229940111695 potassium tartrate Drugs 0.000 description 1
- 235000011005 potassium tartrates Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- UWSAIOMORQUEHN-UHFFFAOYSA-L sodium;2-[2-[carboxylatomethyl(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetate;iron(5+) Chemical compound [Na+].[Fe+5].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O UWSAIOMORQUEHN-UHFFFAOYSA-L 0.000 description 1
- MKBNNYRMBCFUSH-UHFFFAOYSA-J sodium;iron(3+);oxalate Chemical compound [Na+].[Fe+3].[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O MKBNNYRMBCFUSH-UHFFFAOYSA-J 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940086389 succinic acid 150 mg Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 206010044697 tropical sprue Diseases 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Virology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- AIDS & HIV (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/020,801 US20060134227A1 (en) | 2004-12-22 | 2004-12-22 | Compositions including iron |
| PCT/US2005/038859 WO2006068697A2 (en) | 2004-12-22 | 2005-10-27 | Compositions including iron |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2008525442A true JP2008525442A (ja) | 2008-07-17 |
Family
ID=36596132
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007548207A Pending JP2008525442A (ja) | 2004-12-22 | 2005-10-27 | 鉄を含む組成物 |
| JP2007548226A Pending JP2008525445A (ja) | 2004-12-22 | 2005-11-09 | 鉄吸収増進のための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007548226A Pending JP2008525445A (ja) | 2004-12-22 | 2005-11-09 | 鉄吸収増進のための方法および組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US20060134227A1 (enExample) |
| EP (2) | EP1827418A4 (enExample) |
| JP (2) | JP2008525442A (enExample) |
| CN (1) | CN101102762A (enExample) |
| AR (1) | AR052837A1 (enExample) |
| AU (1) | AU2005319679A1 (enExample) |
| BR (1) | BRPI0519265A2 (enExample) |
| CA (1) | CA2591996A1 (enExample) |
| MX (1) | MX2007008021A (enExample) |
| PE (1) | PE20061122A1 (enExample) |
| WO (2) | WO2006068697A2 (enExample) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011230953A (ja) * | 2010-04-27 | 2011-11-17 | Nippon Roki Kogyo Kk | 石化遺骨灰の製造方法 |
| JP2014508526A (ja) * | 2011-03-10 | 2014-04-10 | ディーエスエム アイピー アセッツ ビー．ブイ． | 飲料に鉄補給する方法 |
| JP2016065003A (ja) * | 2014-09-24 | 2016-04-28 | 富田製薬株式会社 | 経口型鉄分補給用固形組成物及びその製造方法 |
| JP2016537429A (ja) * | 2013-11-22 | 2016-12-01 | シノセラピューティックス、インコーポレイテッドＳｉｎｏｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | フェロポルフィリン固体分散体およびその製造方法 |
| JP2017109998A (ja) * | 2015-12-15 | 2017-06-22 | エーザイフード・ケミカル株式会社 | 鉄化合物含有組成物の粒子、鉄化合物の変色抑制方法、並びに鉄化合物及びビタミンｃ含有組成物 |
| CN108635370A (zh) * | 2018-07-13 | 2018-10-12 | 山东达因海洋生物制药股份有限公司 | 一种含有右旋糖酐铁的组合物制剂及其制备方法 |
| JP2019519603A (ja) * | 2016-05-26 | 2019-07-11 | 普惠▲徳▼生技股▲分▼有限公司 | 乳酸を減少させるために使用する第一鉄アミノ酸キレートを含む組成物 |
| JP2021511358A (ja) * | 2018-12-20 | 2021-05-06 | 普惠徳生技股▲ふん▼有限公司 | 第一鉄アミノ酸粒子を含む組成物、および膵臓関連疾患の治療または改善のための薬剤製造におけるその組成物の使用 |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10249552A1 (de) | 2002-10-23 | 2004-05-13 | Vifor (International) Ag | Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel |
| WO2007035760A1 (en) * | 2005-09-20 | 2007-03-29 | Board Of Regents, The University Of Texas System | Enhanced solubility of preformed calcium citrate by adding citric acid |
| ES2380952T3 (es) * | 2005-10-11 | 2012-05-21 | Bayer Consumer Care Ag | Mezcla de sales de hierro y cobre que enmascaran el sabor metálico. |
| EP1790356A1 (de) * | 2005-11-24 | 2007-05-30 | Vifor (International) Ag | Präparat, umfassend Eisen(III)-Komplexverbindungen und redoxaktive Substanz(en) |
| CA2953964A1 (en) | 2006-01-06 | 2007-07-19 | Luitpold Pharmaceuticals, Inc. | Methods and compositions for administration of iron |
| ES2395862T3 (es) * | 2006-09-28 | 2013-02-15 | Bayer Consumer Care Ag | Mezcla de sales de hierro y de cobre para enmascarar el sabor metálico |
| US8142803B2 (en) | 2007-03-22 | 2012-03-27 | Magceutics, Inc. | Magnesium compositions and uses thereof for neurological disorders |
| ES2769583T3 (es) * | 2007-03-22 | 2020-06-26 | Neurocentria Inc | Composiciones de magnesio y usos de las mismas |
| US7816404B2 (en) | 2007-07-20 | 2010-10-19 | Rockwell Medical Technologies, Inc. | Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions |
| US20090047362A1 (en) * | 2007-08-13 | 2009-02-19 | Keith Edward Forrester | Method for in-vitro stabilization of heavy metals |
| US8466187B2 (en) | 2007-09-18 | 2013-06-18 | Thermolife International, Llc | Amino acid compositions |
| US9125844B1 (en) | 2007-09-25 | 2015-09-08 | Argent Development Group, Llc | Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women |
| US7964189B1 (en) | 2007-09-25 | 2011-06-21 | Argent Development Group, Llc | Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women |
| ITMI20071979A1 (it) * | 2007-10-12 | 2009-04-13 | Massimo Baldacci | Formulazioni farmaceutiche contenenti ferro bisglicinato chelato |
| US20090124572A1 (en) * | 2007-11-09 | 2009-05-14 | Deanna Jean Nelson | Iron-containing nutritional supplement |
| US8535659B1 (en) | 2008-05-27 | 2013-09-17 | Argent Development Group, Llc | Nutritional supplements for pregnant women |
| US8535660B1 (en) | 2008-05-27 | 2013-09-17 | Argent Development Group, Llc | Nutritional supplements for pregnant women |
| US9913806B2 (en) * | 2008-06-25 | 2018-03-13 | Fe3 Medical, Inc. | Patches and methods for the transdermal delivery of a therapeutically effective amount of iron |
| WO2010036977A2 (en) * | 2008-09-25 | 2010-04-01 | New England Medical Center Hospitals, Inc. | Combination therapies with topiramate for seizures, restless legs syndrome, and other neurological conditions |
| JP5702307B2 (ja) * | 2009-01-30 | 2015-04-15 | エコラボ インコーポレイティド | アルミニウムヒドロキシカルボキシレートビルダーの開発 |
| US8202830B2 (en) | 2009-01-30 | 2012-06-19 | Ecolab Usa Inc. | Development of an aluminum hydroxydicarboxylate builder |
| US8821945B2 (en) | 2009-04-25 | 2014-09-02 | Fe3 Medical, Inc. | Method for transdermal iontophoretic delivery of chelated agents |
| WO2010136839A1 (en) * | 2009-05-29 | 2010-12-02 | Carlo Ghisalberti | Use of deferoxamine and related compounds in targeted delivery forms to treat an inflammatory bowel disease |
| US8178709B2 (en) * | 2009-07-21 | 2012-05-15 | Biolink Life Sciences, Inc. | Iron preparation suitable for pharmaceutical formulation and process for the preparation thereof |
| CN102573807A (zh) | 2009-07-21 | 2012-07-11 | 凯克斯生物制药公司 | 柠檬酸铁剂型 |
| US8536106B2 (en) | 2010-04-14 | 2013-09-17 | Ecolab Usa Inc. | Ferric hydroxycarboxylate as a builder |
| EP2420243A1 (en) | 2010-08-18 | 2012-02-22 | Inovativo Biomedicinas Tehnologiju Instituts, SIA | Compositions obtainable from bred beetroot juice to promote iron absorption and blood forming |
| IT1402142B1 (it) * | 2010-09-24 | 2013-08-28 | Just Pharma S R L | Formulazione integrativa finalizzata al controllo delle alterazioni multifattoriali ricorrenti nell'anemia da carenza di ferro e per colmare eventuali carenze o aumentati fabbisogni nutrizionali in alcune condizioni fisiopatologiche. |
| WO2012163938A1 (de) | 2011-05-31 | 2012-12-06 | Vifor (International) Ag | Fe(iii)-2,4-dioxo-1-carbonyl-komplexverbindungen zur behandlung und prophylaxe von eisenmangelerscheinungen und eisenmangelanämien |
| CA2849732C (en) * | 2011-09-22 | 2019-10-01 | Jonathan Bortz | Buffered upper gi absorption promoter |
| EA201590062A1 (ru) * | 2012-06-21 | 2016-02-29 | Керикс Байофармасьютикалз, Инк. | Применение лимонно-кислого железа при лечении пациентов с хронической почечной недостаточностью |
| US20150250839A1 (en) * | 2012-09-11 | 2015-09-10 | Dakota Star Capital Llc | Nutritional supplement containing iron |
| CN102961338B (zh) * | 2012-12-07 | 2015-03-18 | 青岛黄海制药有限责任公司 | 一种多糖铁缓释微丸制剂及其制备方法 |
| CA2913413C (en) * | 2013-06-06 | 2021-11-23 | Amip, Llc | Iron supplement |
| ES2683212T3 (es) * | 2013-08-28 | 2018-09-25 | Dsm Ip Assets B.V. | Complementación de hierro de un concentrado de caldo |
| PL3048903T3 (pl) * | 2013-08-28 | 2017-09-29 | Dsm Ip Assets B.V. | Suplementacja żelaza koncentratu bulionu |
| TWI483721B (zh) | 2013-09-05 | 2015-05-11 | Profeat Biotechnology Co Ltd | The use of a composition containing a ferrous amino acid chelate for the manufacture of anti-cancer medicaments |
| AU2013400082B2 (en) * | 2013-09-05 | 2016-01-28 | Profeat Biotechnology Co., Ltd. | Use of composition containing ferrous amino acid chelate in preparation of anti-cancer medicament |
| US9492421B1 (en) | 2013-11-14 | 2016-11-15 | Argent Development Group, Llc | Nutritional supplements for treatment of iron deficiency anemia |
| US9629846B1 (en) | 2013-11-14 | 2017-04-25 | Argent Development Group, Llc | Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women |
| JP2014051535A (ja) * | 2013-12-19 | 2014-03-20 | Fujifilm Corp | 鉄、カルシウム、又はマグネシウムの吸収を促進する方法 |
| CN104887696B (zh) * | 2014-03-04 | 2018-06-29 | 天津怀仁制药有限公司 | 右旋糖酐铁和维生素c的复方制剂 |
| EP3179249A4 (en) * | 2014-08-05 | 2017-07-26 | Fujifilm Corporation | Nucleated erythrocyte sorting method |
| US9961886B2 (en) | 2014-08-13 | 2018-05-08 | Akeso Biomedical, Inc. | Antimicrobial compounds and compositions, and uses thereof |
| GB201416293D0 (en) * | 2014-09-15 | 2014-10-29 | Solvotrin Therapeutics Ltd | Methods and preparations |
| EP3216782B1 (en) * | 2014-11-07 | 2021-06-02 | NPA - Núcleo De Pesquisas Aplicadas LTDA. | Iron amino acid compounds, method for preparing iron amino acid compounds, compositions containing iron amino acid compounds, and uses thereof |
| AU2014413288B2 (en) | 2014-12-01 | 2018-06-28 | Profeat Biotechnology Co., Ltd. | Use of composition containing iron (II) amino acid chelate in preparing drug for regulating and controlling fat metabolism |
| CN104474004A (zh) * | 2014-12-09 | 2015-04-01 | 重庆综艺营养科技有限责任公司 | 改善贫血的赖氨酸螯合铁生血素 |
| US20170360075A1 (en) * | 2014-12-11 | 2017-12-21 | The Penn State Research Foundation | Medical food for the treatment of malaria and/or iron deficiency |
| ES2880321T3 (es) | 2015-08-11 | 2021-11-24 | Akeso Biomedical Inc | Composiciones de inhibición de biopelícula que potencian el aumento de peso en el ganado |
| US10653658B2 (en) | 2015-08-11 | 2020-05-19 | Akeso Biomedical, Inc. | Biofilm inhibiting compositions enhancing weight gain in livestock |
| CN105476953B (zh) * | 2015-09-01 | 2018-10-30 | 张伟 | 一种用于补铁的液体制剂及其制备方法 |
| US11517555B2 (en) * | 2015-09-04 | 2022-12-06 | Rockwell Medical, Inc. | Solid soluble ferric pyrophosphate formulations, kits, and methods using the same |
| EP3199167A1 (de) | 2016-01-28 | 2017-08-02 | G.L. Pharma GmbH | Arzneimittel zur behandlung von eisenmangelzuständen mit folsäuredefizit |
| MY196575A (en) * | 2016-03-15 | 2023-04-19 | Solvotrin Therapeutics Ltd | Compositions and Methods for Increasing Iron Intake in a Mammal |
| ES2891773T3 (es) * | 2016-05-20 | 2022-01-31 | Obshestvo S Ogranichennoj Otvetstvennostju Vikzdorove Zhivotnyh | Composición inyectable que comprende un complejo de dextrano de hierro y vitaminas para prevenir y tratar la anemia |
| CN106265731B (zh) * | 2016-09-30 | 2019-07-19 | 广西科技大学 | 硫酸亚铁骨架型缓释滴丸的制备方法 |
| US20190365697A1 (en) * | 2017-02-17 | 2019-12-05 | Profeat Biotechnology Co., Ltd. | Method for Treating Liver Dysfunction |
| MA50229A (fr) * | 2017-09-11 | 2020-07-22 | Pharmacosmos Holding As | Composés complexes de fer à usage thérapeutique |
| CN110464011A (zh) * | 2018-08-07 | 2019-11-19 | 美安康质量检测技术（上海）有限公司 | 一种补血营养粉及其制备方法 |
| EP3860621A4 (en) * | 2018-10-05 | 2022-07-06 | Ampersand Biopharmaceuticals, Inc. | IRON FORMULATIONS FOR TOPICAL ADMINISTRATION AND METHODS OF TREATMENT OF IRON DEFICIENCY |
| EP3873493A4 (en) * | 2018-10-31 | 2023-04-19 | My-Or Diagnostics Ltd. | PERSONALIZED FOODS TO ENSURE ADEQUATE IRON ABSORPTION |
| TWI717139B (zh) * | 2018-12-20 | 2021-01-21 | 普惠德生技股份有限公司 | 含有亞鐵胺基酸螯合物粒子的組合物用於製備治療或減緩自體免疫相關疾病的醫藥品的用途 |
| CN112168843A (zh) * | 2019-07-05 | 2021-01-05 | 普惠德生技股份有限公司 | 经烧结的纳米粒子及其抗病毒的用途 |
| IL315206A (en) | 2021-02-11 | 2024-10-01 | Thermolife Int Llc | A method of administering nitric oxide gas |
| US12059399B2 (en) * | 2021-06-30 | 2024-08-13 | Getwing Biotechnology Medical Co., Ltd | Methods for alleviating kidney disease and fibrosis of organ |
| WO2023272693A1 (zh) * | 2021-07-01 | 2023-01-05 | 思瑰瑞保健食品有限公司 | 一种维生素c加硫酸亚铁缓控释片及其制备方法 |
| WO2023023029A1 (en) * | 2021-08-16 | 2023-02-23 | Thermolife International, Llc | Iron supplement compositions and methods of use thereof |
| CN114028423B (zh) * | 2021-12-13 | 2023-05-23 | 广东粤港澳大湾区国家纳米科技创新研究院 | 修饰的纳米氧化铁在制备预防和/或治疗炎性肠病的药物中的应用 |
| CN114288320A (zh) * | 2021-12-29 | 2022-04-08 | 珠海天翼医药技术开发有限公司 | 一种猪用口服补铁剂及其制备方法 |
| CN114767710B (zh) * | 2022-04-12 | 2023-07-07 | 中山大学 | 甘氨酸亚铁在治疗类风湿关节炎中的应用 |
| CN116636620B (zh) * | 2023-05-25 | 2025-02-14 | 南昌大学 | 一种乌鸡蛋清肽组合物及其应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB933108A (en) * | 1960-02-03 | 1963-08-08 | Haessle Ab | Improvements in or relating to pharmaceutical iron preparations |
| US6521247B1 (en) * | 1999-08-13 | 2003-02-18 | Warner Chilcott Laboratories Ireland Limited | Dual iron containing nutritional supplement |
| US20030206969A1 (en) * | 2002-05-02 | 2003-11-06 | Integrity Pharmaceutical Corporation | Prenatal multivitamin/multimineral supplement |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1266356A (enExample) * | 1968-08-08 | 1972-03-08 | ||
| GB1292820A (en) * | 1969-08-28 | 1972-10-11 | Aspro Nicholas Ltd | Haematinic preparations |
| GB1338071A (en) * | 1970-11-25 | 1973-11-21 | Laso Martinez V | Pharmaceutical iron preparations |
| US3773929A (en) * | 1972-11-02 | 1973-11-20 | Diagnostic Data Inc | Pharmaceutical compositions comprising orgotein and their use |
| US4362710A (en) * | 1980-07-04 | 1982-12-07 | Nissan Gosei Kogyo Co., Ltd. | Feeds for baby pigs, process for preparing the same and method of breeding baby pigs |
| US4599152A (en) * | 1985-05-24 | 1986-07-08 | Albion Laboratories | Pure amino acid chelates |
| US4863898A (en) * | 1986-02-06 | 1989-09-05 | Albion International, Inc. | Amino acid chelated compositions for delivery to specific biological tissue sites |
| US4752479A (en) * | 1986-05-27 | 1988-06-21 | Ciba-Geigy Corporaton | Multi vitamin and mineral dietary supplement with controlled release bioavailable iron |
| US4830716B1 (en) * | 1986-07-03 | 1999-12-07 | Albion Int | Preparation of pharmaceutical grade amino acid chelates |
| US5070085A (en) * | 1987-04-10 | 1991-12-03 | Oxycal Laboratories, Inc. | Compositions and methods for administering therapeutically active compounds |
| US4822816A (en) * | 1987-04-10 | 1989-04-18 | Oxycal Laboratories, Inc. | Compositions and methods for administering vitamin C |
| FR2642420B1 (fr) * | 1989-01-27 | 1991-09-06 | Valpan Sa Labo Pharma | Nouvelle forme galenique a liberation programmee contenant une association de sels ferreux, d'acide succinique et d'acide ascorbique |
| JPH0674206B2 (ja) * | 1989-12-28 | 1994-09-21 | 田辺製薬株式会社 | 放出制御型製剤およびその製法 |
| US6451341B1 (en) * | 1990-02-05 | 2002-09-17 | Thomas J. Slaga | Time release formulation of vitamins, minerals and other beneficial supplements |
| HU207799B (en) * | 1991-07-24 | 1993-06-28 | Beres Export Import Rt | Process for producing pharmaceutical composition for influencing the reticuloendothelial system, for treating chronic pain symptomes of degenerative locomotor disorders or tumors, and for treating mucoviscidosis |
| US5662922A (en) * | 1992-01-20 | 1997-09-02 | Christensen; Borge Holm | Iron-containing composition for the prevention of anaemia and a method for producing the composition |
| US5516925A (en) * | 1994-08-23 | 1996-05-14 | Albion International, Inc. | Amino acid chelates having improved palatability |
| JP2590449B2 (ja) * | 1995-04-21 | 1997-03-12 | 農林水産省畜産試験場長 | 新生子牛の造血機能の改善及び貧血の予防方法 |
| PL184140B1 (pl) * | 1995-10-27 | 2002-09-30 | Procter & Gamble | Napój w proszku |
| US5770226A (en) * | 1996-07-10 | 1998-06-23 | Wake Forest University | Combined pharmaceutical estrogen-androgen-progestin oral contraceptive |
| CA2230801A1 (en) * | 1998-02-27 | 1999-08-27 | Stanley H. Zlotkin | Composition comprising micro-encapsulated iron |
| US6495177B1 (en) * | 1999-08-13 | 2002-12-17 | Warner Chilcott Laboratories Ireland Limited | Orally dissolvable nutritional supplement |
| CN1396908A (zh) * | 2000-01-28 | 2003-02-12 | 宝洁公司 | 美味的精氨酸化合物及其用于心血管健康的应用 |
| US20020013331A1 (en) * | 2000-06-26 | 2002-01-31 | Williams Robert O. | Methods and compositions for treating pain of the mucous membrane |
| US6924273B2 (en) * | 2000-10-03 | 2005-08-02 | Scott W. Pierce | Chondroprotective/restorative compositions and methods of use thereof |
| US6716814B2 (en) * | 2001-08-16 | 2004-04-06 | Albion International, Inc. | Enhancing solubility of iron amino acid chelates and iron proteinates |
| US6906038B2 (en) * | 2001-08-29 | 2005-06-14 | Abbott Laboratories | Methods for alleviating mucositis |
| US20030190355A1 (en) * | 2002-04-05 | 2003-10-09 | Hermelin Marc S. | Modified release minerals |
| US20060148690A1 (en) * | 2002-07-08 | 2006-07-06 | Lydie Bougueleret | Secreted peptides |
| US20030045473A1 (en) * | 2002-07-19 | 2003-03-06 | Sarama Robert Joseph | Compositions, kits, and methods for cardiovascular health |
| US8007846B2 (en) * | 2006-01-18 | 2011-08-30 | Albion International, Inc. | Mixed amino acid/mineral compounds having improved solubility |
-
2004
- 2004-12-22 US US11/020,801 patent/US20060134227A1/en not_active Abandoned
-
2005
- 2005-10-27 WO PCT/US2005/038859 patent/WO2006068697A2/en not_active Ceased
- 2005-10-27 CA CA002591996A patent/CA2591996A1/en not_active Abandoned
- 2005-10-27 AU AU2005319679A patent/AU2005319679A1/en not_active Abandoned
- 2005-10-27 JP JP2007548207A patent/JP2008525442A/ja active Pending
- 2005-10-27 EP EP05813755A patent/EP1827418A4/en not_active Withdrawn
- 2005-10-27 MX MX2007008021A patent/MX2007008021A/es unknown
- 2005-10-27 CN CNA2005800470364A patent/CN101102762A/zh active Pending
- 2005-10-27 BR BRPI0519265-0A patent/BRPI0519265A2/pt not_active IP Right Cessation
- 2005-11-09 US US11/793,517 patent/US20090028962A1/en not_active Abandoned
- 2005-11-09 WO PCT/US2005/041139 patent/WO2006068729A2/en not_active Ceased
- 2005-11-09 JP JP2007548226A patent/JP2008525445A/ja active Pending
- 2005-11-09 EP EP05820746A patent/EP1827419A4/en not_active Withdrawn
- 2005-12-01 PE PE2005001394A patent/PE20061122A1/es not_active Application Discontinuation
- 2005-12-21 AR ARP050105442A patent/AR052837A1/es unknown
-
2010
- 2010-09-27 US US12/891,376 patent/US20110015150A1/en not_active Abandoned
-
2012
- 2012-07-20 US US13/554,243 patent/US20130189374A1/en not_active Abandoned
-
2015
- 2015-02-27 US US14/634,312 patent/US20160022631A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB933108A (en) * | 1960-02-03 | 1963-08-08 | Haessle Ab | Improvements in or relating to pharmaceutical iron preparations |
| US6521247B1 (en) * | 1999-08-13 | 2003-02-18 | Warner Chilcott Laboratories Ireland Limited | Dual iron containing nutritional supplement |
| US20030206969A1 (en) * | 2002-05-02 | 2003-11-06 | Integrity Pharmaceutical Corporation | Prenatal multivitamin/multimineral supplement |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011230953A (ja) * | 2010-04-27 | 2011-11-17 | Nippon Roki Kogyo Kk | 石化遺骨灰の製造方法 |
| JP2014508526A (ja) * | 2011-03-10 | 2014-04-10 | ディーエスエム アイピー アセッツ ビー．ブイ． | 飲料に鉄補給する方法 |
| JP2016537429A (ja) * | 2013-11-22 | 2016-12-01 | シノセラピューティックス、インコーポレイテッドＳｉｎｏｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | フェロポルフィリン固体分散体およびその製造方法 |
| JP2016065003A (ja) * | 2014-09-24 | 2016-04-28 | 富田製薬株式会社 | 経口型鉄分補給用固形組成物及びその製造方法 |
| JP2017109998A (ja) * | 2015-12-15 | 2017-06-22 | エーザイフード・ケミカル株式会社 | 鉄化合物含有組成物の粒子、鉄化合物の変色抑制方法、並びに鉄化合物及びビタミンｃ含有組成物 |
| JP2021073283A (ja) * | 2015-12-15 | 2021-05-13 | 三菱ケミカルフーズ株式会社 | 鉄化合物含有組成物の粒子、鉄化合物の変色抑制方法、並びに鉄化合物及びビタミンｃ含有組成物 |
| JP2019519603A (ja) * | 2016-05-26 | 2019-07-11 | 普惠▲徳▼生技股▲分▼有限公司 | 乳酸を減少させるために使用する第一鉄アミノ酸キレートを含む組成物 |
| CN108635370A (zh) * | 2018-07-13 | 2018-10-12 | 山东达因海洋生物制药股份有限公司 | 一种含有右旋糖酐铁的组合物制剂及其制备方法 |
| JP2021511358A (ja) * | 2018-12-20 | 2021-05-06 | 普惠徳生技股▲ふん▼有限公司 | 第一鉄アミノ酸粒子を含む組成物、および膵臓関連疾患の治療または改善のための薬剤製造におけるその組成物の使用 |
| JP6998087B2 (ja) | 2018-12-20 | 2022-02-04 | 普惠徳生技股▲ふん▼有限公司 | 第一鉄アミノ酸粒子を含む組成物、およびその組成物を含む、膵臓関連疾患の治療または改善のための薬剤 |
| US12194015B2 (en) | 2018-12-20 | 2025-01-14 | Profeat Biotechnology Co., Ltd. | Composition comprising ferrous amino acid particles and method for treating or ameliorating pancreas-related disease using the same |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008525445A (ja) | 2008-07-17 |
| BRPI0519265A2 (pt) | 2009-01-06 |
| EP1827419A4 (en) | 2011-08-17 |
| AU2005319679A1 (en) | 2006-06-29 |
| US20090028962A1 (en) | 2009-01-29 |
| CN101102762A (zh) | 2008-01-09 |
| WO2006068697A3 (en) | 2006-12-21 |
| PE20061122A1 (es) | 2006-10-16 |
| AR052837A1 (es) | 2007-04-04 |
| US20160022631A1 (en) | 2016-01-28 |
| WO2006068729A3 (en) | 2007-01-18 |
| EP1827418A4 (en) | 2011-08-24 |
| WO2006068729A2 (en) | 2006-06-29 |
| MX2007008021A (es) | 2008-04-11 |
| CA2591996A1 (en) | 2006-06-29 |
| EP1827418A2 (en) | 2007-09-05 |
| US20110015150A1 (en) | 2011-01-20 |
| US20060134227A1 (en) | 2006-06-22 |
| WO2006068697A2 (en) | 2006-06-29 |
| EP1827419A2 (en) | 2007-09-05 |
| US20130189374A1 (en) | 2013-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008525442A (ja) | 鉄を含む組成物 | |
| US20090035385A1 (en) | Compositions including iron | |
| US10898459B2 (en) | Method of treating chronic kidney disease | |
| US7994217B2 (en) | Prenatal multivitamin/multimineral supplement | |
| CN1972676B (zh) | 用于个体化应答式给药方案的营养药的组合物和系统 | |
| EP2330924A1 (en) | Iron-containing nutritional supplement | |
| JP2012519201A (ja) | リン酸塩吸着剤 | |
| CA2421410C (en) | Iron compositions | |
| RU2437653C1 (ru) | Способ лечения и профилактики желудочно-кишечных болезней новорожденных телят | |
| HK1116672A (en) | Compositions including iron | |
| US5665385A (en) | Dietary metal supplements | |
| DE3936319C3 (de) | Phosphatbinder zur oralen Verabreichung | |
| JPH0240045B2 (enExample) | ||
| Choudhury | Iron Formulations in Pediatric Practice Jitender Nagpal | |
| HK1228669A1 (en) | Method of treating chronic kidney disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080905 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111115 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120508 |